Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B-Reference-Cited by-同舟云学术

Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B

Published:2024-08-27 Issue:9 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Takazono Takahiro¹²^ORCID,Ito Genta³^ORCID,Hosogaya Naoki⁴,Iwanaga Naoki¹,Komeda Takuji³,Kobayashi Masayuki³,Kitanishi Yoshitake³,Ogura Eriko⁵,Mukae Hiroshi¹⁶

Affiliation:

1. Department of Respiratory Medicine Nagasaki University Hospital Nagasaki Japan

2. Department of Infectious Diseases Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

3. Data Science Department, Shionogi & Co., Ltd. Osaka Japan

4. Clinical Research Center Nagasaki University Hospital Nagasaki Japan

5. Global Development Division, Shionogi & Co., Ltd. Tokyo Japan

6. Department of Respiratory Medicine Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

Abstract

ABSTRACTThis retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti‐influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti‐influenza therapy were also less frequent with baloxavir, thus supporting its use.Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.70002

Reference12 articles.

1. Burden of influenza B virus infection and considerations for clinical management

2. Japanese Surveillance Systems and Treatment for Influenza

3. Baloxavir: First Global Approval

4. Roche “Roche's Xofluza Approved by the European Commission for the Treatment of Influenza the First New Influenza Antiviral for Patients in Almost 20 Years ” (2021) https://www.roche.com/media/releases/med‐cor‐2021‐01‐11.

5. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study